血滞通胶囊联合阿托伐他汀钙对腹膜透析合并高脂血症患者的影响

Effect of Xuezhitong Capsule Combined with Atorvastatin Calcium on Peritoneal Dialysis Patients Complicated with Hyperlipidemia

目的探讨血滞通胶囊联合阿托伐他汀钙对腹膜透析合并高脂血症患者的血脂及微炎症状态的影响。方法选取2019年1月至2020年12月在成都医学院第一附属医院就诊的60例腹膜透析合并高脂血症患者为研究对象,按随机数字表法分为对照组(口服阿托伐他汀钙)和试验组(口服血滞通胶囊+阿托伐他汀钙),每组30例,比较两组治疗前和治疗3个月后的血脂、肝功能、炎症因子水平及不良反应。结果治疗3个月后,试验组临床治疗总有效率明显高于对照组(P<0.05);治疗后试验组甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、白介素6(IL-6)、肿瘤坏死因子α(TNF-α)以及超敏C反应蛋白(hs-CRP)均明显低于对照组(P<0.05);试验组的高密度脂蛋白(HDL-C)较对照组升高(P<0.05);治疗后两组谷草转氨酶(AST)、谷丙转氨酶(ALT)均在正常范围,但试验组AST低于对照组,差异有统计学意义(P<0.05);试验组不良反应发生率为10.0%,对照组不良反应发生率为13.3%,两组比较差异无统计学意义(P>0.05)。结论血滞通胶囊联合阿托伐他汀钙可改善腹膜透析合并高脂血症患者的血脂水平,抑制微炎症状态,且使用安全。

Objective To investigate the effect of Xuezhitong Capsule combined with atorvastatin calcium on serum lipid and microinflammation in patients undergoing peritoneal dialysis(PD)and complicated with hyperlipidemia.Methods A total of 60 PD patients complicated with hyperlipidemia who were treated in the nephrology department of the First Affiliated Hospital of Chengdu Medical College were selected.They were randomly divided into control group(n=30,oral atorvastatin calcium)and experimental group(n=30,oral Xuezhitong Capsule and atorvastatin calcium).Levels of serum lipid,liver function and inflammatory factors before treatment and 3 months after treatment were compared between the two groups.Adverse reactions after treatment were also compared between the two groups.Results After 3 months of treatment,the total effective rate in the experimental group was significantly higher than that in the control group(P<0.05).The levels of triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),interleukin-6(IL-6),tumor necrosis factorα(TNF-a)and high-sensitivity C-reactive protein(hs-CRP)in the experimental group were significantly lower than those in the control group(P<0.05).High-density lipoprotein cholesterol(HDL-C)in the experimental group was higher than that in the control group(P<0.05).Aspartate aminotransferase(AST)and alanine aminotransferase(ALT)after treatment in both groups were in the normal range,with AST in the experimental group lower than that in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 10%in the experimental group and 13.3%in the control group,showing no statistical significance between the two groups(P>0.05).Conclusion Xuezhitong Capsule combined with atorvastatin calcium can decrease serum lipid level as well as inhibit microinflammation in PD patients complicated with hyperlipidemia,and with high safety.